New study to reveal how well mpox vaccine works in HIV patients

NCT ID NCT05654883

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 26, 2026 · Updated 26 times

Summary

This study looks at how well the mpox vaccine works and how safe it is in people with HIV compared to those without HIV. About 174 adults who either recently got the mpox vaccine or had a recent mpox infection will take part. The goal is to fill important knowledge gaps and help improve public health guidance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

Conditions

The condition(s) this trial relates to.

HIV infectious disease monkeypox

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.